<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01994252</url>
  </required_header>
  <id_info>
    <org_study_id>RN00208414</org_study_id>
    <nct_id>NCT01994252</nct_id>
  </id_info>
  <brief_title>Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation</brief_title>
  <acronym>RAFT-PermAF</acronym>
  <official_title>Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) and heart failure (HF) are two common heart conditions that are&#xD;
      encountered with an increase in death and suffering. When both these two conditions occur in&#xD;
      a patient, the patient's prognosis is poor with a reduced quality of life and impaired heart&#xD;
      function. These patients have enlarged hearts, specifically the left ventricle (major pumping&#xD;
      chamber), which impairs the heart's pumping capacity, leading to symptoms such as fatigue,&#xD;
      shortness of breath from any type of exertion, and swelling, usually of the feet and ankles.&#xD;
&#xD;
      In these HF patients who are in AF all of the time, who would otherwise be a suitable&#xD;
      candidate for an implantable defibrillator to prevent sudden cardiac death, we would like to&#xD;
      determine whether adding pacing of both ventricles will reduce heart size (left ventricular&#xD;
      end systolic volume index LVESVi) as measured by ultrasound, which can improve its function&#xD;
      and help the heart pump more efficiently.&#xD;
&#xD;
      Other studies have shown that adding pacing to both ventricles is of benefit in HF patients&#xD;
      with mild to moderate symptoms and have a regular heart rhythm. The Investigators now want to&#xD;
      explore if this therapy will benefit those patients with a permanent irregular heart rhythm&#xD;
      (AF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NEW:&#xD;
&#xD;
      Heart failure (HF) is increasing in prevalence and incidence, and is the most common reason&#xD;
      for hospital admissions of patients over the age of 65. Therapy for HF has evolved over the&#xD;
      last two decades. Cardiac resynchronization therapy (CRT) is a therapy that attempts to&#xD;
      resynchronize the sequence of ventricular contraction in heart failure (HF) patients with&#xD;
      left ventricular (LV) systolic dysfunction and ventricular dyssynchrony. CRT is achieved by&#xD;
      stimulating both RV and LV together, synchronized to right atrial excitation to achieve&#xD;
      atrio-ventricular synchrony. Clinical trials have demonstrated that CRT reduced heart size&#xD;
      (left ventricular end systolic volume index LVESVi), improved survival and reduced HF&#xD;
      hospitalization in mild to advanced HF patients. In addition, CRT reversed the remodeling&#xD;
      process such that it was associated with a reduction of LV size, and an increase of LV&#xD;
      ejection fraction (EF). This knowledge translated to a change in practice guidelines and the&#xD;
      adoption of CRT into clinical practice benefitting many HF patients CRT is now an important&#xD;
      state-of-the-art therapy for HF patients with LV systolic dysfunction, low LVEF, and&#xD;
      prolonged QRS duration in sinus rhythm, since the vast majority of the CRT clinical research&#xD;
      was performed in patients in sinus rhythm. However, in the ~25% of HF patients with permanent&#xD;
      atrial fibrillation (AF), the effectiveness of CRT is not clear. It is therefore timely to&#xD;
      address the question of whether the addition of CRT to optimal HF treatment, rate control and&#xD;
      an ICD is beneficial in reducing LVESVi in HF patients in permanent AF with LV systolic&#xD;
      dysfunction and prolonged QRS duration&#xD;
&#xD;
      Objectives: To determine whether cardiac resynchronization therapy will reduce Left&#xD;
      Ventricular End-Systolic Volume index (LVESVi) for heart failure patients with permanent&#xD;
      atrial fibrillation, mild to moderate heart failure, left ventricular systolic dysfunction,&#xD;
      and prolonged QRS duration, when compared to implantable cardioverter defibrillator (ICD)&#xD;
      therapy alone.&#xD;
&#xD;
      Methods: This is a multi-centre randomized controlled trial of two treatment groups. The&#xD;
      patients, primary physicians and the heart failure caregivers will be blinded to the&#xD;
      treatment allocation. The device follow-up caregivers will not be blinded. Patients with NYHA&#xD;
      Class II and III HF symptoms, LVEF HF ≤ 35% , permanent AF, on optimal medical therapy and&#xD;
      QRS durations ≥ 130 ms when the QRS morphology is LBBB, or QRS durations ≥ 150 ms when the&#xD;
      QRS morphology is non-LBBB, or Paced QRS will be included in the trial. Patients should be&#xD;
      suitable candidates for either of the 2 treatment strategies. There will be 200 patients&#xD;
      randomized in 1:1 ratio to two groups: 1) ICD-CRT, 2) ICD only. All patients will undergo&#xD;
      baseline clinical evaluation, echocardiogram measurements, quality of life assessment,&#xD;
      medication assessment, and NT-proBNP. The patients will be followed at 1 month, 3 months, 6&#xD;
      months and then every 6 months. Follow up echocardiograms will be done at 6 and 12 month&#xD;
      follow ups to evaluate LVESVi. Quality of life assessment, and 6-minute walk distance will&#xD;
      also be performed at baseline and at follow-up visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is a reduction of Left Ventricular End Systolic Volume index (LVESVi)</measure>
    <time_frame>Baseline to a minimum of 18 months</time_frame>
    <description>Echocardiogram Measures of LVESVi</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Baseline to a minimum of 18 months</time_frame>
    <description>Death all cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for Heart Failure</measure>
    <time_frame>Baseline to a minimum of 18 months</time_frame>
    <description>Admission to Hospital &gt; 24 hours for Heart Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>Baseline to a minimum of 18 months</time_frame>
    <description>Cardiovascular Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>Baseline to a minimum of 18 months</time_frame>
    <description>Readmission for Heart Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire</measure>
    <time_frame>Baseline to a minimum of 18 months</time_frame>
    <description>Minnesota Living with Heart Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute walk distance</measure>
    <time_frame>Baseline to a minimum of 18 months</time_frame>
    <description>Hall walk distance over 6 minute timeframe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular hospitalizations</measure>
    <time_frame>Baseline to a minimum of 18 months</time_frame>
    <description>Cardiovascular Admission to Hospital &gt; 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause mortality and heart failure</measure>
    <time_frame>Baseline to a minimum of 18 months</time_frame>
    <description>All cause death and admission to to Hospital &gt; 24 hours for Heart Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire</measure>
    <time_frame>Baseline to a minimum of 18 months</time_frame>
    <description>EQ5D-5L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Heart Disease</condition>
  <condition>Congestive Heart Failure</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Optimal Medical therapy plus ICD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter only group will receive an ICD + optimal medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Medical therapy plus CRT/ICD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter plus cardiac resynchronisation therapy (CRT) group will receive an ICD + CRT and optimal medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimal Medical therapy plus ICD</intervention_name>
    <arm_group_label>Optimal Medical therapy plus ICD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimal Medical therapy plus CRT/ICD</intervention_name>
    <arm_group_label>Optimal Medical therapy plus CRT/ICD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with NYHA Class II or III HF symptoms (assessment in the last 3 months)&#xD;
&#xD;
          -  Permanent AF&#xD;
&#xD;
          -  Optimal Medical Therapy for HF of at least 3 months (according to 2009 ACCF/AHA and&#xD;
             ESC 2012 recommendations,)&#xD;
&#xD;
          -  LVEF ≤ 35% (assessment in the last 6 months)&#xD;
&#xD;
          -  Candidacy for an ICD for primary or secondary prevention of sudden cardiac death&#xD;
&#xD;
          -  QRS durations ≥ 130 ms when the QRS morphology is LBBB, or QRS durations ≥ 150 ms when&#xD;
             the QRS morphology is non-LBBB or Paced QRS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In-hospital patients who have acute cardiac or non-cardiac illness that requires&#xD;
             intensive care&#xD;
&#xD;
          -  Intra-venous inotropic agent in the last 4 days&#xD;
&#xD;
          -  Patients with a life expectancy of less than one year from non-cardiac cause.&#xD;
&#xD;
          -  Expected to undergo cardiac transplantation within one year (status I)&#xD;
&#xD;
          -  Acute coronary syndrome (including MI) &lt; 4 weeks&#xD;
&#xD;
          -  Unable or unwilling to provide informed consent&#xD;
&#xD;
          -  Uncorrected or uncorrectable primary valvular disease&#xD;
&#xD;
          -  Restrictive, hypertrophic or reversible form of cardiomyopathy&#xD;
&#xD;
          -  Severe primary pulmonary disease such as cor pulmonale&#xD;
&#xD;
          -  Tricuspid prosthetic valve&#xD;
&#xD;
          -  Patients included in other clinical trial that will affect the objectives of this&#xD;
             study&#xD;
&#xD;
          -  Coronary revascularization (CABG or PCI) &lt; 3 months&#xD;
&#xD;
          -  Patients with an existing ICD or CRT pacemaker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony SL Tang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony SL Tang, MD</last_name>
    <phone>519-663-3746</phone>
    <email>anthonysltang@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>George A Wells, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Libin Cardiovascular Institute of Alberta</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Derrek Exner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthew Bennett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Victoria Cardiac Arrhythmia Trials</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 4R2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Novak, MD</last_name>
      <phone>250-595-0400</phone>
    </contact>
    <investigator>
      <last_name>Paul Novak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Colette Seifer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Science</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ratika Parkash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeff Healey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Damian Redfearn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Yee, MD</last_name>
      <phone>519-663-3746</phone>
    </contact>
    <investigator>
      <last_name>Peter Leong-Sit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1W 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David H Birnie, MD</last_name>
      <phone>613 696 77269</phone>
    </contact>
    <investigator>
      <last_name>David H. Birnie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Angaran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill Health Science Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vidal Essebag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernard Thibault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM Centre hospitalier universitaire de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benoit Coutu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Sacré-Cœur de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marcio Sturmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>François Philippon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Ayala-Paredes, MD</last_name>
    </contact>
    <investigator>
      <last_name>Felix Ayala-Paredes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010 Dec 16;363(25):2385-95. doi: 10.1056/NEJMoa1009540. Epub 2010 Nov 14.</citation>
    <PMID>21073365</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 8, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>defibrillator</keyword>
  <keyword>cardiac resynchronization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

